Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.590
-0.080 (-1.71%)
Aug 12, 2026, 4:00 PM EDT - Market closed
Arbutus Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 19.17 | 18.01 | 36.33 | 26.29 | 30.78 | 109.28 |
Short-Term Investments | 73.45 | 73.46 | 86.29 | 99.72 | 116.14 | 46.04 |
Cash & Short-Term Investments | 92.63 | 91.47 | 122.62 | 126 | 146.91 | 155.32 |
Cash Growth | -5.57% | -25.41% | -2.68% | -14.23% | -5.41% | 26.00% |
Accounts Receivable | 0.37 | 1.45 | 2.41 | 1.78 | 1.35 | 0.9 |
Other Receivables | 179.37 | - | - | - | - | - |
Total Trade Receivables | 179.74 | 1.45 | 2.41 | 1.78 | 1.35 | 0.9 |
Other Current Assets | 1.52 | 1.54 | 2.28 | 4.25 | 2.87 | 4.45 |
Total Current Assets | 273.88 | 94.46 | 127.32 | 132.03 | 151.14 | 160.66 |
Net Property, Plant & Equipment | - | - | 1.05 | 6.09 | 6.81 | 8.08 |
Long-Term Investments | - | - | - | 6.28 | 37.36 | 35.69 |
Other Long-Term Assets | 0.13 | 0.13 | 0.03 | - | 0.1 | 0.06 |
Total Assets | 274.03 | 94.62 | 131.71 | 144.4 | 195.42 | 204.49 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.85 | 5.46 | 7.56 | 10.27 | 16.03 | 10.84 |
Current Portion of Leases | 0.51 | 0.55 | 0.48 | 0.43 | 0.37 | 0.38 |
Unearned Revenue | - | - | 7.57 | 11.79 | 16.46 | - |
Total Current Liabilities | 3.36 | 6.01 | 15.62 | 22.49 | 32.86 | 11.22 |
Long-Term Debt | 3.11 | 3.44 | 4.83 | 6.95 | 10.37 | 16.3 |
Long-Term Leases | - | 0.2 | 0.81 | 1.34 | 1.82 | 2.23 |
Other Long-Term Liabilities | 8.82 | 8.4 | 13.09 | 7.6 | 13.53 | 5.3 |
Total Long-Term Liabilities | 11.93 | 12.04 | 18.72 | 15.9 | 25.71 | 23.83 |
Total Liabilities | 15.29 | 18.04 | 34.34 | 38.38 | 58.57 | 35.05 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1,448 | 1,421 | 1,410 | 1,350 | 1,319 | 1,287 |
Additional Paid-in Capital | 74.32 | 83.32 | 82.05 | 81.27 | 72.41 | 65.49 |
Accumulated Other Comprehensive Income | -48.24 | -48.1 | -48.14 | -48.42 | -50.49 | -48.34 |
Retained Earnings | -1,216 | -1,380 | -1,347 | -1,277 | -1,204 | -1,134 |
Shareholders' Equity | 258.73 | 76.58 | 97.37 | 106.02 | 136.85 | 169.44 |
Total Liabilities & Equity | 274.03 | 94.62 | 131.71 | 144.4 | 195.42 | 204.49 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.63 | 4.19 | 6.12 | 8.72 | 12.55 | 18.91 |
Net Cash (Debt) | 89 | 87.28 | 116.51 | 117.28 | 134.36 | 136.41 |
Net Cash Growth | -4.39% | -25.08% | -0.66% | -12.71% | -1.50% | 35.42% |
Net Cash Per Share | 0.46 | 0.46 | 0.63 | 0.71 | 0.89 | 1.28 |
Book Value | 258.73 | 76.58 | 97.37 | 106.02 | 136.85 | 169.44 |
Book Value Per Share | 1.33 | 0.40 | 0.52 | 0.64 | 0.91 | 1.59 |
Tangible Book Value | 258.73 | 76.58 | 97.37 | 106.02 | 136.85 | 169.44 |
Tangible Book Value Per Share | 1.33 | 0.40 | 0.52 | 0.64 | 0.91 | 1.59 |